one heart magazine 2013

Download One Heart Magazine 2013

Post on 28-Mar-2016

218 views

Category:

Documents

2 download

Embed Size (px)

DESCRIPTION

The third annual edition of One Heart Magazine.

TRANSCRIPT

  • ONE HEART MAGAZINE Globa l Card iovascu lar A l l i ance 2013

    COMPASSIONATE CARDIOLOGYLEADERS INPHILANTHROPY

    One HeartGlobal CardiovascularAl l iance

  • Effient and the Effient logo are registered trademarks of Eli Lilly and Company.Copyright 2013 Daiichi Sankyo, Inc. and Lilly USA, LLC. All Rights Reserved.PG84132. PGHCPISI03Oct2011. Printed in USA. May 2013.

    Effient (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with unstable angina (UA) or nonST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI. The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.

    IMPORTANT SAFETY INFORMATION

    WARNING: BLEEDING RISKEffient (prasugrel) can cause significant, sometimes fatal, bleeding.Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke.In patients 75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered.Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.Additional risk factors for bleeding include: body weight

  • Effient and the Effient logo are registered trademarks of Eli Lilly and Company.Copyright 2013 Daiichi Sankyo, Inc. and Lilly USA, LLC. All Rights Reserved.PG84132. PGHCPISI03Oct2011. Printed in USA. May 2013.

    Effient (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with unstable angina (UA) or nonST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI. The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.

    IMPORTANT SAFETY INFORMATION

    WARNING: BLEEDING RISKEffient (prasugrel) can cause significant, sometimes fatal, bleeding.Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke.In patients 75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered.Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.Additional risk factors for bleeding include: body weight

  • Effient (prasugrel) tablets Brief Summary of Prescribing InformationBRIEF SUMMARY: Please see Full Prescribing Information for additional information about Effient.

    WARNING: BLEEDING RISKEffient can cause significant, sometimes fatal, bleeding [see Warnings and Precautions (5.1 and 5.2) and Adverse Reactions (6.1)].Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke [see Contraindications (4.1 and 4.2)].In patients 75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI) where its effect appears to be greater and its use may be considered [see Use in Specific Populations (8.5)].Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.Additional risk factors for bleeding include:

    body weight

  • The bleeding rate is highest initially, as shown in Figure 1 (inset: Days 0 to 7) [see Warnings and Precautions (5.1)].Bleeding rates in patients with the risk factors of age 75 years and weight
  • Visit the following sites for more information:TYRX.com or HeartDeviceInfection.com

    Bioresorbable mesh fully resorbs into the body in ~9 weeks

    Requires no adjustment to standard surgical techniques during replacement or revision procedures.

    Identical antibiotic combination as original AIGISRX Envelope

    It contains the same locally released antimicrobial agent combinationRifampin and Minocyclineto help reduce CIED infection following implantation.1-6

    Multiple studies support clinical efficacy

    Patients at high risk for CIED infection who are implanted with the AIGISRX Envelope had 70% to 100% fewer infections compared to patients without it.7-9

    Significantly reduces costs of infection in CIED implants

    Your facility can reduce costs by as much as $100,000 for every 100 AIGISRX Envelopes used with your high-risk CIED patients.8-12

    1 Hanna H et al. J Clin Oncol. 2004;22(15):3163-3171. 2 Leon C et al. Intensive Care Med. 2004;30(10):1891-1899. 3 Zabramski JM et al. J Neurosurg. 2003;98(4):725-730. 4 Chatzinikolaou I et al. Am J Med. 2003;115(5):352-357. 5 Raad I et al. Ann Intern Med.1997;128(4):267-274. 6 Gould PA et al. J Am Med Assoc. 2006;295(2):1907-1911. 7 Bloom H et al. Pacing Clin Electrophysiol. 2011;34(2):133-142. 8 Kolek MJ et al. Pacing Clin Electrophysiol.2013;36(3):354-361. 9 Henrickson, Citadel & Centurion study. Presented at the Late Breaking Clinical Trials session at the European Heart Rhythm Association (EHRA), EUROPACE 2013. 10 Mittal et al. 2013 HRS Scientific Session, PO 05-43, NY/NJ Valley Health System. 11 Inpatient Prospective Payment System (IPPS) Final Rule, FY13. 12 Data on file, 092713-1.

  • Visit the following sites for more information:TYRX.com or HeartDeviceInfection.com

    Bioresorbable mesh fully resorbs into the body in ~9 weeks

    Requires no adjustment to standard surgical techniques during replacement or revision procedures.

    Identical antibiotic combination as original AIGISRX Envelope

    It contains the same locally released antimicrobial agent combinationRifampin and Minocyclineto help reduce CIED infection following implantation.1-6

    Multiple studies support clinical efficacy

    Patients at high risk for CIED infection who are implanted with the AIGISRX Envelope had 70% to 100% fewer infections compared to patients without it.7-9

    Significantly reduces costs of infection in CIED implants

    Your facility can reduce costs by as much as $100,000 for every 100 AIGISRX Envelopes used with your high-risk CIED patients.8-12

    1 Hanna H et al. J Clin Oncol. 2004;22(15):3163-3171. 2 Leon C et al. Intensive Care Med. 2004;30(10):1891-1899. 3 Zabramski JM et al. J Neurosurg. 2003;98(4):725-730. 4 Chatzinikolaou I et al. Am J Med. 2003;115(5):352-357. 5 Raad I et al. Ann Intern Med.1997;128(4):267-274. 6 Gould PA et al. J Am Med Assoc. 2006;295(2):1907-1911. 7 Bloom H et al. Pacing Clin Electrophysiol. 2011;34(2):133-142. 8 Kolek MJ et al. Pacing Clin Electrophysiol.2013;36(3):354-361. 9 Henrickson, Citadel & Centurion study. Presented at the Late Breaking Clinical Trials session at the European Heart Rhythm Association (EHRA), EUROPACE 2013. 10 Mittal et al. 2013 HRS Scientific Session, PO 05-43, NY/NJ Valley Health System. 11 Inpatient Prospective Payment System (IPPS) Final Rule, FY13. 12 Data on file, 092713-1.

  • Certified Cardiographic Technician (CCT)

    Certified Rhythm Analysis Technician (CRAT)

    Registered Congenital Cardiac Sonographer (RCCS)

    Registered Cardiac Electrophysiology Specialist (RCES)

    Registered Cardiovascular Invasive Specialist (RCIS)

    Registered Cardiac Sonographer (RCS)

    Registered Phlebology Sonographer (RPhS)

    Registered Vascular Specialist (RVS)

    Credentials administered by CCI are accredited by the American National Standards Institute (ANSI) based on the ISO/IEC 17024 Accreditation Standard.

    Cardiovascular Credentialing International

    Credentialing Cardiovascular Professionals since 1968

    1-800-326-0268 www.cci-online.org

    Photo courtesy of Lancaster General Hospital

    Photo courtesy of Saint Francis Hospital and Medical Center

  • TABLE OF CONTENTS

    18His Legacy Lives OnBy Harry G. Mond, M.D. and Benedict S. Maniscalco, M.D.

    Interview with

    Dr. Joseph MesserWorking for the Global Cardiovascular Good

    26

    HBI of Guatemala Expands

    By Laura Maniscalco DeLise and Michael Maniscalco

    34

    www.heartbeatsaveslives.org ONE HEART MAGAZINE 9

    Macapasos de Vida Para TiHBI of El Salvador44 By Francisco Rivera

  • To find out more, visit www.accumetrics.com/hrs

    Platelet Reactivity TestingCritical Information for Critical Patient Care Decisions

    The RighT FiTfor every paTienTStudies show that up to 1 in 3 patients may not respond adequately to their anti-platelet medications. With more medication options available, its critical to assess your patient care strategy with the verifynow system.

    The accumetrics logo and verifynow are registered trademarks of accumetrics, inc., 2013 accumetrics, inc.

    System

    1(858) 643-1600